uniQure (NASDAQ:QURE) Trading 8.7% Higher – Here’s Why

uniQure N.V. (NASDAQ:QURE) shares rose 8.7% during trading on Tuesday . The company traded as high as $51.38 and last traded at $51.5660. 1,429,167 shares traded hands during trading, a decline of 41% from the average daily volume of 2,414,303 shares. The stock had previously closed at $47.46.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Barclays dropped their price objective on uniQure from $65.00 to $60.00 and set an “overweight” rating for the company in a report on Thursday, July 30th. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Chardan Capital increased their price objective on uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Cantor Fitzgerald raised uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 target price for the company in a research report on Wednesday, June 17th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of uniQure in a research report on Friday, June 26th. Thirteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $65.00.

uniQure Trading Up 8.0%

The company has a market capitalization of $3.56 billion, a PE ratio of -12.78 and a beta of 0.93. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.01 and a quick ratio of 10.01. The company’s fifty day moving average is $43.78 and its 200-day moving average is $28.88.

uniQure (NASDAQ:QURE) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40). The company had revenue of $5.84 million for the quarter, compared to analysts’ expectations of $5.45 million. uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.During the same quarter in the prior year, the company earned ($0.69) EPS. On average, analysts anticipate that uniQure N.V. will post -3.74 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Madhavan Balachandran sold 11,685 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total transaction of $526,526.10. Following the sale, the director owned 43,254 shares of the company’s stock, valued at $1,949,025.24. This trade represents a 21.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Walid Abi-Saab sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $46.42, for a total value of $1,392,600.00. Following the sale, the insider directly owned 148,235 shares in the company, valued at approximately $6,881,068.70. The trade was a 16.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 388,229 shares of company stock valued at $16,817,099. Company insiders own 4.65% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Woodline Partners LP boosted its stake in uniQure by 25.0% in the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock valued at $1,864,000 after acquiring an additional 35,175 shares in the last quarter. Legal & General Group Plc purchased a new stake in shares of uniQure during the 2nd quarter valued at $497,000. Marshall Wace LLP lifted its holdings in shares of uniQure by 276.5% during the 2nd quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock valued at $3,108,000 after purchasing an additional 163,749 shares during the last quarter. California State Teachers Retirement System acquired a new stake in shares of uniQure in the 2nd quarter worth $540,000. Finally, Ameriprise Financial Inc. boosted its position in shares of uniQure by 38.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock worth $10,622,000 after purchasing an additional 212,218 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.